Key result
It is too early to predict whether the balance between transcatheter and surgical aortic valve replacement volume will shift in low-risk patients, as decision-making remains highly complex.
Answers are grounded in this paper and cite their sources.
Predicting the shift to TAVR in low-risk aortic stenosis patients requires considering complex clinical factors, patient preferences, and pending randomized trial data, rather than relying solely on prevalence estimates and risk scores.
HomeCirculation: Cardiovascular Quality and OutcomesVol. 10, No. 6Too Early to Tell Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBToo Early to TellThe Complexity of Decision Making for Aortic Stenosis Patients at Low Surgical Risk Megan Coylewright, MD, MPH and Alexander Iribarne, MD, MS Megan CoylewrightMegan Coylewright From the Section of Cardiovascular Medicine (M.C.) and Section of Cardiac Surgery (A.I.), Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. and Alexander IribarneAlexander Iribarne From the Section of Cardiovascular Medicine (M.C.) and Section of Cardiac Surgery (A.I.), Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, NH. Originally published9 Jun 2017https://doi.org/10.1161/CIRCOUTCOMES.117.003835Circulation: Cardiovascular Quality and Outcomes. 2017;10:e003835The report from De Sciscio et al1 in this issue of Circulation: Cardiovascular Quality and Outcomes, suggestively titled "Quantifying the shift toward transcatheter aortic valve replacement in low-risk patients...," illustrates the great interest of many stakeholders to predict the ultimate role of transcatheter aortic valve replacement (TAVR) in the treatment of severe aortic stenosis (AS). TAVR was commercially approved for patients with high to prohibitive surgical risk in 2011 and expanded to intermediate-risk patients in August of 2016. Now, ≈30% of TAVR centers in the United States are participating in 1 of 2 randomized trials comparing TAVR to surgery in low-risk patients.2,3 Our knowledge of the implications of TAVR in low-risk patients is limited, but apt to change in coming years with the results of ongoing trials.See Article by De Sciscio et alNot surprisingly, there is an inevitable desire by policy makers, industry, the medical community, and others to take our past experience with TAVR in high-risk patients and apply it to lower risk populations to understand how this disruptive technology will affect surgical practice. In this context, De Sciscio et al1 sought to summarize available studies examining the prevalence of AS, and rates of progression to valve replacement, to define who may be eligible for surgical aortic valve replacement (SAVR), TAVR, or both in the coming years. Although this is a worthwhile endeavor, it is in the concept of eligibility where the predictions may be severely limited in defining how many patients there will be to shift from a surgical to a transcatheter approach.In their meta-analysis, the authors review the past 2 decades of literature on AS, selecting reports that included patients who had undergone echocardiography and met objective criteria for staging AS. After a rigorous process, they chose 56 studies representing 42 956 patients aged ≥60 years. To extrapolate rates of disease prevalence, the authors used techniques of fixed and random-effects models and Monte Carlo simulation using population estimates from 37 countries within the 2015 International Monetary Fund advanced economies index. The methodology for determining eligibility for TAVR or SAVR relied heavily on the EuroSCORE, an individualized risk model predicting the chance of dying at 30 days after SAVR. This risk score, in addition to the Society for Thoracic Surgeons risk score, are used in large clinical trials to classify patients and are the basis for government approval for commercial use of TAVR. However, these models are a small piece of the clinical decision making process when selecting a treatment strategy for severe AS.The pooled prevalence of any type of AS was 4.5%, with an estimate of 19.9% of those patients having severe AS: an overall prevalence of severe AS of 0.9%. The authors estimated that over 750 000 patients in the United States had severe AS in 2015, and over half of these patients were eligible for SAVR. Some of these patients were also reported to be eligible for TAVR: >230 000 patients, of which nearly 90 000 fell in the low risk category by EuroSCORE and age >65 years.The most recent Society for Thoracic Surgeons Adult Cardiac Surgery Database Executive Summary puts the authors' estimates in perspective: in 2015, there were just under 50 000 SAVRs in the United States, suggesting that by the authors' estimates, only 10% of individuals eligible to receive SAVR underwent surgery.4 Similarly, the authors estimate that in the United States in 2015, there were 111 205 high risk or inoperable patients aged >75 years old; this patient group reflects the commercial practice for TAVR at that time. These estimates claim that only 1 in 5 eligible patients received TAVR given that 25 000 TAVRs were performed in 414 centers that same year.5 The results highlight a significant disconnect between the number of estimated eligible patients and the reported number of patients who are receiving treatment. Although this was a finding noted before the era of TAVR,6 the suggested disparity in the use of TAVR and SAVR is inconsistent with current clinical practice. The threshold for treatment of AS is lower than in the past as the risk of both procedures continues to fall.The authors note that this present study does not examine the etiologies of this purported treatment gap, yet cite that patient refusal may play a role. This is likely an interplay of the key factors influencing a decision to not intervene in severe AS, including weighing the risk of intervention and estimated benefit against a patient's frailty, comorbid conditions, and values and preferences.7 Those competing comorbid conditions may preclude patients from accomplishing their stated goals of valve replacement and, thus, lead to a selection of medical therapy.8 Research is just beginning to identify the role of patient preferences in decisions to not undergo valve replacement.9 Reimbursement in the United States is largely determined by Medicare given the age of the population; how future health policy decisions, including restrictive coverage decisions and cost sharing, will affect low-risk patients, and their decision making, is not yet clear.The dissonance for clinicians when faced with these numbers of undertreatment may relate to how they are framed: prevalence (existing cases) versus incidence (newly diagnosed cases). Incidence is illustrated briefly in this article, with a reported estimate of 300 000 new cases of AS (not necessarily severe AS) in 2016 across the 37 countries. Similarly, a study by Osnabrugge et al10 in 2013 focusing on high-risk patients suggested that 27 000 new patients each year met criteria for TAVR (19 European countries and North America). The use of incident cases resonates clinically, as compared with the large prevalence estimates. Expanded indications of TAVR to low-risk patients are unlikely to change past clinical decision making that found certain patients unlikely to benefit from valve replacement (yet still included in prevalence estimates).Despite these concerns regarding estimates of disease prevalence, what are the clinical and policy implications of predicting a shift of patients from SAVR to TAVR? It is essential to note that heart teams—and their patients with severe AS at low surgical risk—are facing brand new territory when it comes to decision making as the options expand. Determining eligibility for therapy in low-risk patients is an order of magnitude more complex than referencing a surgical risk score, as was used in this study. Specific technical factors that differ between TAVR and SAVR become more relevant in assessing comparative effectiveness as surgical risk falls, with low mortality for both procedures. These factors include the availability of minimally invasive access approaches, the differing risks of pacemaker and new atrial fibrillation, valve performance over time, and the effectiveness of transcatheter heart valves in bicuspid valves, among others. The uncertainty is largely because of the lack of randomized controlled data in these patient populations and availability of long-term follow-up data from completed trials. How patient preferences will influence decision making between TAVR and SAVR in low-risk patients, including the challenging allure of valve replacement with minimal recovery, is not yet known.Less than a year into commercial use of TAVR in intermediate risk patients, and with research just beginning to focus on low-risk populations, it is too early to predict whether the balance between transcatheter and surgical volume may truly shift. De Sciscio et al present global estimates of the prevalence of AS, and while their estimates for therapy eligibility must be understood in the context of the study limitations, it is clear that the burden of severe AS will continue. The choice of intervention will likely be driven by the performance of SAVR and TAVR in ongoing trials, economics, and patient preferences, among other factors. Heart teams will be challenged to successfully integrate these complex, and at times competing, variables as we work together to continue to provide high-quality, patient-centered care.DisclosuresNone.FootnotesThe opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.Correspondence to Megan Coylewright, MD, MPH, Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, One Medical Center Dr, Lebanon, NH. E-mail [email protected]References1. De Sciscio P, Brubert J, De Sciscio M, Serrani M, Stasiak J, Moggridge G. Quantifying the shift towards transcatheter aortic valve replacement in low-risk patients: a meta-analysis.Circ Cardiovasc Qual Outcomes. 2017; 10:e003287. doi: 10.1161/CIRCOUTCOMES.116.003287.LinkGoogle Scholar2. ClinicalTrials.gov. The PARTNER 3 Trial—The safety and effectiveness of the SAPIEN 3 transcatheter heart valve in low-risk patients with aortic stenosis (P3).2017. Available at https://clinicaltrials.gov/ct2/show/NCT02675114. Accessed April 28, 2017.Google Scholar3. ClinicalTrials.gov. Medtronic transcatheter aortic valve replacement in low risk patients.2017. Available at https://clinicaltrials.gov/ct2/show/NCT02701283. Accessed April 28, 2017.Google Scholar4. Society of Thoracic Surgeons. 2016 Harvest 2—Executive summary adult cardiac surgery database.2016. Available at http://www.sts.org/sites/default/files/documents/2016Harvest2_ExecutiveSummary_new.pdf. Accessed April 28, 2017.Google Scholar5. Grover FL, Vemulapalli S, Carroll JD, Edwards FH, Mack MJ, Thourani VH, Brindis RG, Shahian DM, Ruiz CE, Jacobs JP, Hanzel G, Bavaria JE, Tuzcu EM, Peterson ED, Fitzgerald S, Kourtis M, Michaels J, Christensen B, Seward WF, Hewitt K, Holmes DR2016 Annual report of the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry.J Am Coll Cardiol. 2017; 69:1215–1230. doi: 10.1016/j.jacc.2016.11.033.CrossrefMedlineGoogle Scholar6. Bach DS, Siao D, Girard SE, Duvernoy C, McCallister BD, Gualano SK. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk.Circ Cardiovasc Qual Outcomes. 2009; 2:533–539. doi: 10.1161/CIRCOUTCOMES.109.848259.LinkGoogle Scholar7. Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Fleisher LA, Jneid H, Mack MJ, McLeod CJ, O'Gara PT, Rigolin VH, Sundt TM, Thompson A. 2017 AHA/ACC Focused Update of the 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.J Am Coll Cardiol. 2017. doi: 10.1016/j.jacc.2017.03.011.Epub ahead of print.CrossrefGoogle Scholar8. Coylewright M, Palmer R, O'Neill ES, Robb JF, Fried TR. Patient-defined goals for the treatment of severe aortic stenosis: a qualitative analysis.Health Expect. 2016; 19:1036–1043. doi: 10.1111/hex.12393.CrossrefMedlineGoogle Scholar9. Dharmarajan K, Foster J, Coylewright M, Green P, Vavalle JP, Faheem O, Huang PH, Krishnaswamy A, Thourani VH, McCoy LA, Wang TY. The medically managed patient with severe symptomatic aortic stenosis in the TAVR era: Patient characteristics, reasons for medical management, and quality of shared decision making at heart valve treatment centers.PLoS One. 2017; 12:e0175926. doi: 10.1371/journal.pone.0175926.CrossrefMedlineGoogle Scholar10. Osnabrugge RL, Mylotte D, Head SJ, Van Mieghem NM, Nkomo VT, LeReun CM, Bogers AJ, Piazza N, Kappetein AP. Aortic stenosis in the elderly: disease prevalence and number of candidates for transcatheter aortic valve replacement: a meta-analysis and modeling study.J Am Coll Cardiol. 2013; 62:1002–1012. doi: 10.1016/j.jacc.2013.05.015.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetails June 2017Vol 10, Issue 6 Advertisement Article InformationMetrics © 2017 American Heart Association, Inc.https://doi.org/10.1161/CIRCOUTCOMES.117.003835PMID: 28600456 Originally publishedJune 9, 2017 KeywordsEditorialstranscatheter aortic valve implantationprevalenceriskaortic stenosisaortic valvePDF download Advertisement SubjectsAortic Valve Replacement/Transcatheter Aortic Valve Implantation
No takes yet. Share an insight, caveat, or question.
Coylewright et al. (2017) conducted an editorial in Aortic stenosis. Transcatheter aortic valve replacement (TAVR) vs. Surgical aortic valve replacement (SAVR) was evaluated. It is too early to predict whether the balance between transcatheter and surgical aortic valve replacement volume will shift in low-risk patients, as decision-making remains highly complex.
Synapse has enriched 10 related papers. Consider them for comparative context: